MD MBA - Perspective Therapeutics Chief Officer
| CATX Stock | 4.12 0.28 6.36% |
Executive
MD MBA is Chief Officer of Perspective Therapeutics
| Age | 58 |
| Address | 2401 Elliott Avenue, Seattle, WA, United States, 98121 |
| Phone | 206 676 0900 |
| Web | https://www.perspectivetherapeutics.com |
Perspective Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1435) % which means that it has lost $0.1435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2702) %, meaning that it created substantial loss on money invested by shareholders. Perspective Therapeutics' management efficiency ratios could be used to measure how well Perspective Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.88 in 2024. Return On Capital Employed is likely to rise to -0.47 in 2024. At this time, Perspective Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 85.1 M in 2024, whereas Total Current Assets are likely to drop slightly above 14.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gordon Weber | SurModics | 61 | |
| Matthew Link | Sight Sciences | 49 | |
| Stephanie Walsh | Orthofix Medical | N/A | |
| Michael JD | Si Bone | 46 | |
| RN MBA | CVRx Inc | N/A | |
| Jennifer Englund | CVRx Inc | N/A | |
| Bradley Nagel | Electromed | 42 | |
| Teryl Sides | SurModics | 54 | |
| Matt Brinckman | Paragon 28 | N/A | |
| Matthew Millard | Paragon 28 | N/A | |
| Manohar Raheja | Sight Sciences | N/A | |
| Victoria MD | PAVmed Inc | N/A | |
| John Shumaker | Paragon 28 | N/A | |
| Julie Andrews | Orthofix Medical | 53 | |
| Matthew Brinckman | Paragon 28 | N/A | |
| Deanna Wilke | LivaNova PLC | N/A | |
| Michael Pisetsky | Si Bone | 46 | |
| Alex CMA | LivaNova PLC | 54 | |
| Kelley Nicholas | Neuropace | N/A | |
| Stephen JD | Sight Sciences | N/A | |
| Leah Akin | Neuropace | N/A | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.14 |
Perspective Therapeutics Leadership Team
Elected by the shareholders, the Perspective Therapeutics' board of directors comprises two types of representatives: Perspective Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perspective. The board's role is to monitor Perspective Therapeutics' management team and ensure that shareholders' interests are well served. Perspective Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perspective Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Shane Cobb, Executive Operations | ||
| Annie Cheng, Vice Relations | ||
| Mark CPA, Controller, Finance | ||
| Andrew Bright, Executive Brachytherapy | ||
| Johan Spoor, CEO Director | ||
| Michael Schultz, Chief Officer | ||
| Steve Keefe, Senior Development | ||
| PGradDip BA, Chief Officer | ||
| Jonathan Hunt, CFO Officer | ||
| David Hauser, Senior Operations | ||
| Frances MD, Chief Officer |
Perspective Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perspective Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (50.50) % | ||||
| Current Valuation | 14.88 M | ||||
| Shares Outstanding | 67.59 M | ||||
| Shares Owned By Insiders | 20.45 % | ||||
| Shares Owned By Institutions | 81.42 % | ||||
| Number Of Shares Shorted | 8.28 M | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 178.84 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.